Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Eikon Therapeutics, Inc.EIKN · Entity 5380 | Director | March 02, 2026 | March 04, 2026 |
| Merck & Co., Inc.MRK · Entity 2807 | Director · Executive Chair | November 07, 2022 | November 08, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Eikon Therapeutics, Inc.
Report date March 02, 2026 · Filed March 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.88 · Expires 2036-03-01 | Direct | 25,873 |
Reported balance
After 2026-03-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-02 · Grant · Acquired 25,873 · Balance 25,873 F1: 1/48th of the shares underlying the option will vest on each monthly anniversary of the vesting start date for 48 months, subject to the Reporting Person's continued service through each date. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/48th of the shares underlying the option will vest on each monthly anniversary of the vesting start date for 48 months, subject to the Reporting Person's continued service through each date.
Merck & Co., Inc.
Report date November 07, 2022 · Filed November 08, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 936,422.063 |
Reported balance
After 2022-11-07 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-11-07 · Exercise / conversion · Acquired 235,769 · Balance 936,422.063 |
| Common StockSEC Table I · non-derivative | Direct | 911,508.063 |
Reported balance
After 2022-11-07 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2022-11-07 · Sale · Disposed 24,914 · Balance 911,508.063 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.7400 to $98.7400, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. |
| Common StockSEC Table I · non-derivative | Direct | 785,374.063 |
Reported balance
After 2022-11-07 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2022-11-07 · Sale · Disposed 126,134 · Balance 785,374.063 F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.7500 to $99.7500, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. |
| Common StockSEC Table I · non-derivative | Direct | 700,653.063 |
Reported balance
After 2022-11-07 transaction · row 4
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 4 · 2022-11-07 · Sale · Disposed 84,721 · Balance 700,653.063 F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.7600 to $100.3400, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F4: Holdings include shares acquired in dividend reinvestment transactions. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $53.06 · Expires 2026-05-09 | Direct | 0 |
Reported balance
After 2022-11-07 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-11-07 · Exercise / conversion · Disposed 235,769 · Balance 0 F6: The option became exercisable in equal installments on 5/10/2017, 5/10/2018 and 5/10/2019. |
| Common Stock - 401(k) PlanSEC Table I · non-derivative | IndirectBy 401(k) | 4,481.1286 |
Reported balance
Holding disclosure · report date 2022-11-07 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 4,481.1286 F5: Includes shares acquired and dividends earned through October 7, 2022 in the Merck U.S. Savings Plan, a 401(k) plan. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.7400 to $98.7400, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.7500 to $99.7500, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.7600 to $100.3400, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
F4: Holdings include shares acquired in dividend reinvestment transactions.
F5: Includes shares acquired and dividends earned through October 7, 2022 in the Merck U.S. Savings Plan, a 401(k) plan.
F6: The option became exercisable in equal installments on 5/10/2017, 5/10/2018 and 5/10/2019.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
EXXON MOBIL CORP
Report date May 25, 2022 · Filed May 26, 2022
Section 16 reporting ended · disclosed 2022-05-26. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 07, 2013 Filed May 8, 2013 23:28 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 35,832 | $44.98 | $1,611,723.36 |
DisclosureSEC source: 0001225208-13-011729 · doc4.xml · derivative · entry 5 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,832 shares Expires 2013-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. Read SEC document |
| May 07, 2013 Filed May 8, 2013 23:28 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 16,133 | $44.98 | $725,662.34 |
DisclosureSEC source: 0001225208-13-011729 · doc4.xml · nonDerivative · entry 2 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259,172.458 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 07, 2013 Filed May 8, 2013 23:28 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 35,832 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-011729 · doc4.xml · nonDerivative · entry 1 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,305.458 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 06, 2013 Filed May 8, 2013 23:28 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 644,122 | $0.00 Strike: $44.98 | $0.00 |
DisclosureSEC source: 0001225208-13-011729 · doc4.xml · derivative · entry 4 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 644,122 Underlying: Common Stock · 644,122 shares Expires 2023-05-05 F3 · derivative.exercise_date: The option vests in three equal annual installments beginning May 6, 2014. Read SEC document |
| February 25, 2013 Filed Feb 27, 2013 22:50 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 25,484 | $42.52 | $1,083,579.68 |
DisclosureSEC source: 0001225208-13-005762 · doc4.xml · nonDerivative · entry 1 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 239,231.542 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/2010. Performance shares were paid out at 107 percent of target awards. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 02, 2012 Filed May 4, 2012 13:39 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 694,698 | $0.00 Strike: $39.29 | $0.00 |
DisclosureSEC source: 0001225208-12-011184 · doc4.xml · derivative · entry 3 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 694,698 Underlying: Common Stock · 694,698 shares Expires 2022-05-01 F3 · derivative.exercise_date: The option vests in three equal annual installments beginning May 2, 2013. Read SEC document |
| February 28, 2012 Filed Mar 1, 2012 20:37 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 21,228 | $38.38 | $814,730.64 |
DisclosureSEC source: 0001225208-12-006220 · doc4.xml · nonDerivative · entry 1 FRAZIER KENNETH C · CIK 0001181175 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,747.542 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 2/27/09. Performance shares were paid out at 117 percent of target awards. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| August 15, 2011 Filed Aug 15, 2011 18:04 UTC | Merck & Co., Inc. MRK · Entity 2807 | PurchaseCommon Stock | 12,236 | $31.77 | $388,737.72 |
DisclosureSEC source: 0001225208-11-019890 · doc4.xml · nonDerivative · entry 2 FRAZIER KENNETH C · CIK 0001181175 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,519.542 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| August 15, 2011 Filed Aug 15, 2011 18:04 UTC | Merck & Co., Inc. MRK · Entity 2807 | PurchaseCommon Stock | 19,764 | $31.78 | $628,099.92 |
DisclosureSEC source: 0001225208-11-019890 · doc4.xml · nonDerivative · entry 1 FRAZIER KENNETH C · CIK 0001181175 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,283.542 Read SEC document |
| May 04, 2011 Filed May 6, 2011 14:42 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 559,701 | $0.00 Strike: $36.56 | $0.00 |
DisclosureSEC source: 0001225208-11-013362 · doc4.xml · derivative · entry 4 FRAZIER KENNETH C · CIK 0001181175 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 559,701 Underlying: Common Stock · 559,701 shares Expires 2021-05-03 F4 · derivative.exercise_date: The option vests in three equal annual installments beginning May 4, 2012. Read SEC document |
| May 04, 2011 Filed May 6, 2011 14:42 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantRestricted Stock Unit · Derivative | 41,028 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-11-013362 · doc4.xml · derivative · entry 3 FRAZIER KENNETH C · CIK 0001181175 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,028 Underlying: Common Stock · 41,028 shares Expires 2014-05-04 F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. Read SEC document |
| February 22, 2011 Filed Feb 24, 2011 17:01 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 23,014 | $32.34 | $744,272.76 |
DisclosureSEC source: 0001225208-11-007023 · doc4.xml · nonDerivative · entry 1 FRAZIER KENNETH C · CIK 0001181175 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,271.3462 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 2/29/08. Performance shares were paid out at 122 percent of target awards. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| August 01, 2010 Filed Aug 3, 2010 16:09 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 25,000 | $34.46 | $861,500.00 |
DisclosureSEC source: 0001225208-10-018100 · doc4.xml · derivative · entry 4 FRAZIER KENNETH C · CIK 0001181175 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2010-08-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. Read SEC document |
| August 01, 2010 Filed Aug 3, 2010 16:09 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 9,880 | $34.46 | $340,464.80 |
DisclosureSEC source: 0001225208-10-018100 · doc4.xml · nonDerivative · entry 2 FRAZIER KENNETH C · CIK 0001181175 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,257.3462 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| August 01, 2010 Filed Aug 3, 2010 16:09 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-10-018100 · doc4.xml · nonDerivative · entry 1 FRAZIER KENNETH C · CIK 0001181175 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,137.3462 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 07, 2010 Filed May 11, 2010 20:30 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 228,091 | $0.00 Strike: $33.49 | $0.00 |
DisclosureSEC source: 0001225208-10-012612 · doc4.xml · derivative · entry 4 FRAZIER KENNETH C · CIK 0001181175 · Exe V-P & Pres Global HH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 228,091 Underlying: Common Stock · 228,091 shares Expires 2020-05-06 F4 · derivative.exercise_date: The option vests in three equal annual installments beginning May 7, 2011. Read SEC document |
| May 07, 2010 Filed May 11, 2010 20:30 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantRestricted Stock Unit · Derivative | 35,832 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-10-012612 · doc4.xml · derivative · entry 3 FRAZIER KENNETH C · CIK 0001181175 · Exe V-P & Pres Global HH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,832 Underlying: Common Stock · 35,832 shares Expires 2013-05-07 F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. Read SEC document |
| March 02, 2010 Filed Mar 4, 2010 18:53 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRSU - Leader Shares · Derivative | 14,000 | $37.27 Strike: $0.00 | $521,780.00 |
DisclosureSEC source: 0001225208-10-007058 · doc4.xml · derivative · entry 4 FRAZIER KENNETH C · CIK 0001181175 · Exe V-P & Pres Global HH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,000 shares Expires 2010-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. Read SEC document |
| March 02, 2010 Filed Mar 4, 2010 18:53 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 4,555 | $37.27 | $169,764.85 |
DisclosureSEC source: 0001225208-10-007058 · doc4.xml · nonDerivative · entry 2 FRAZIER KENNETH C · CIK 0001181175 · Exe V-P & Pres Global HH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,929.3549 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| March 02, 2010 Filed Mar 4, 2010 18:53 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 14,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-10-007058 · doc4.xml · nonDerivative · entry 1 FRAZIER KENNETH C · CIK 0001181175 · Exe V-P & Pres Global HH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,484.3549 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 08, 2010 Filed Jan 26, 2010 19:32 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 11,698 | $37.72 | $441,248.56 |
DisclosureSEC source: 0001225208-10-002265 · doc4.xml · nonDerivative · entry 1 FRAZIER KENNETH C · CIK 0001181175 · Exe V-P & Pres Global HH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,484.3549 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/02/2007. Performance shares were paid out at 120 percent of target awards. Read SEC document |
| November 03, 2009 Filed Nov 6, 2009 00:09 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 280,000 | $0.00 Strike: $23.45 | $0.00 |
DisclosureSEC source: 0001209191-09-051306 · c92128_4x0.xml · derivative · entry 15 FRAZIER KENNETH C · CIK 0001181175 · Exec. VP & President, GHH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 280,000 shares Expires 2019-04-23 F4 · price: This option vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger. F4 · derivative.exercise_date: This option vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger. Read SEC document |
| November 03, 2009 Filed Nov 6, 2009 00:09 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 252,000 | $0.00 Strike: $44.30 | $0.00 |
DisclosureSEC source: 0001209191-09-051306 · c92128_4x0.xml · derivative · entry 14 FRAZIER KENNETH C · CIK 0001181175 · Exec. VP & President, GHH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 252,000 shares Expires 2018-02-28 F4 · price: This option vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger. F4 · derivative.exercise_date: This option vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger. Read SEC document |
| November 03, 2009 Filed Nov 6, 2009 00:09 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $51.02 | $0.00 |
DisclosureSEC source: 0001209191-09-051306 · c92128_4x0.xml · derivative · entry 13 FRAZIER KENNETH C · CIK 0001181175 · Exec. VP & President, GHH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 80,000 shares Expires 2017-07-31 F4 · price: This option vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger. F4 · derivative.exercise_date: This option vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger. Read SEC document |
| November 03, 2009 Filed Nov 6, 2009 00:09 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 131,040 | $0.00 Strike: $44.19 | $0.00 |
DisclosureSEC source: 0001209191-09-051306 · c92128_4x0.xml · derivative · entry 12 FRAZIER KENNETH C · CIK 0001181175 · Exec. VP & President, GHH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 131,040 shares Expires 2017-03-01 F4 · price: This option vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger. F4 · derivative.exercise_date: This option vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger. Read SEC document |
| November 03, 2009 Filed Nov 6, 2009 00:09 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 112,000 | $0.00 Strike: $35.09 | $0.00 |
DisclosureSEC source: 0001209191-09-051306 · c92128_4x0.xml · derivative · entry 11 FRAZIER KENNETH C · CIK 0001181175 · Exec. VP & President, GHH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 112,000 shares Expires 2016-03-02 F4 · price: This option vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger. F4 · derivative.exercise_date: This option vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger. Read SEC document |
| November 03, 2009 Filed Nov 6, 2009 00:09 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 89,674 | $0.00 Strike: $75.76 | $0.00 |
DisclosureSEC source: 0001209191-09-051306 · c92128_4x0.xml · derivative · entry 10 FRAZIER KENNETH C · CIK 0001181175 · Exec. VP & President, GHH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 89,674 shares Expires 2011-03-01 F5 · price: This option vests on the exercisable date, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger. F5 · derivative.exercise_date: This option vests on the exercisable date, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger. Read SEC document |
| November 03, 2009 Filed Nov 6, 2009 00:09 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 42,500 | $0.00 Strike: $31.84 | $0.00 |
DisclosureSEC source: 0001209191-09-051306 · c92128_4x0.xml · derivative · entry 9 FRAZIER KENNETH C · CIK 0001181175 · Exec. VP & President, GHH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 42,500 shares Expires 2015-02-24 F4 · price: This option vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger. F4 · derivative.exercise_date: This option vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger. Read SEC document |
| November 03, 2009 Filed Nov 6, 2009 00:09 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $48.24 | $0.00 |
DisclosureSEC source: 0001209191-09-051306 · c92128_4x0.xml · derivative · entry 8 FRAZIER KENNETH C · CIK 0001181175 · Exec. VP & President, GHH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 45,000 shares Expires 2014-02-26 F4 · price: This option vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger. F4 · derivative.exercise_date: This option vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger. Read SEC document |
| November 03, 2009 Filed Nov 6, 2009 00:09 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 89,674 | $0.00 Strike: $62.09 | $0.00 |
DisclosureSEC source: 0001209191-09-051306 · c92128_4x0.xml · derivative · entry 7 FRAZIER KENNETH C · CIK 0001181175 · Exec. VP & President, GHH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 89,674 shares Expires 2010-02-21 F5 · price: This option vests on the exercisable date, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger. F5 · derivative.exercise_date: This option vests on the exercisable date, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger. Read SEC document |
| November 03, 2009 Filed Nov 6, 2009 00:09 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 105,499 | $0.00 Strike: $49.96 | $0.00 |
DisclosureSEC source: 0001209191-09-051306 · c92128_4x0.xml · derivative · entry 6 FRAZIER KENNETH C · CIK 0001181175 · Exec. VP & President, GHH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 105,499 shares Expires 2013-02-27 F4 · price: This option vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger. F4 · derivative.exercise_date: This option vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger. Read SEC document |
| November 03, 2009 Filed Nov 6, 2009 00:09 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 94,949 | $0.00 Strike: $58.91 | $0.00 |
DisclosureSEC source: 0001209191-09-051306 · c92128_4x0.xml · derivative · entry 5 FRAZIER KENNETH C · CIK 0001181175 · Exec. VP & President, GHH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 94,949 shares Expires 2012-02-29 F4 · price: This option vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger. F4 · derivative.exercise_date: This option vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger. Read SEC document |
| November 03, 2009 Filed Nov 6, 2009 00:09 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantRSU - Leader Shares · Derivative | 14,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-09-051306 · c92128_4x0.xml · derivative · entry 4 FRAZIER KENNETH C · CIK 0001181175 · Exec. VP & President, GHH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,000 shares Expires 2010-03-02 F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. Common Stock which was assumed and converted from a restricted stock unit to receive an equivalent number of shares of MSD common stock prior to the Transactions. The restricted stock units described herein vest upon the same vesting schedule. F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. Common Stock which was assumed and converted from a restricted stock unit to receive an equivalent number of shares of MSD common stock prior to the Transactions. The restricted stock units described herein vest upon the same vesting schedule. F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. Common Stock which was assumed and converted from a restricted stock unit to receive an equivalent number of shares of MSD common stock prior to the Transactions. The restricted stock units described herein vest upon the same vesting schedule. Read SEC document |
| November 03, 2009 Filed Nov 6, 2009 00:09 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantRestricted Stock Unit · Derivative | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-09-051306 · c92128_4x0.xml · derivative · entry 3 FRAZIER KENNETH C · CIK 0001181175 · Exec. VP & President, GHH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2010-08-01 F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. Common Stock which was assumed and converted from a restricted stock unit to receive an equivalent number of shares of MSD common stock prior to the Transactions. The restricted stock units described herein vest upon the same vesting schedule. F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. Common Stock which was assumed and converted from a restricted stock unit to receive an equivalent number of shares of MSD common stock prior to the Transactions. The restricted stock units described herein vest upon the same vesting schedule. F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. Common Stock which was assumed and converted from a restricted stock unit to receive an equivalent number of shares of MSD common stock prior to the Transactions. The restricted stock units described herein vest upon the same vesting schedule. Read SEC document |
| November 03, 2009 Filed Nov 6, 2009 00:09 UTC | Merck & Co., Inc. MRK · Entity 2807 | OtherCommon Stock-401(k) Plan | 2,475.4088 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-09-051306 · c92128_4x0.xml · nonDerivative · entry 2 FRAZIER KENNETH C · CIK 0001181175 · Exec. VP & President, GHH 10b5-1 filing: Not disclosed Ownership: Indirect · By 401(k) Disclosed balance after: 0 F2 · price: Received as part of the Transactions in exchange for an equivalent number of shares of MSD common stock held under the MSD 401(k) plan. Read SEC document |
| November 03, 2009 Filed Nov 6, 2009 00:09 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 100,786.3549 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-09-051306 · c92128_4x0.xml · nonDerivative · entry 1 FRAZIER KENNETH C · CIK 0001181175 · Exec. VP & President, GHH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Received in exchange for an equivalent number of shares of Merck Sharp & Dohme Corp. (formerly Merck & Co., Inc.) ("MSD") common stock in connection with the completion of transactions contemplated by the Agreement and Plan of Merger by and among, inter alia, MSD and Merck & Co., Inc. (formerly Schering-Plough Corporation) (the "Transactions"). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.